Lida Pacaud
IGI Technologies (United States)(US)Ichnos Sciences (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Multiple Myeloma Research and Treatments, Biosimilars and Bioanalytical Methods, Protein Degradation and Inhibitors, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2018)3,936 cited
- → Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study(2015)1,241 cited
- → Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma(2023)651 cited
- → Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up(2022)595 cited
- → Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma(2020)423 cited
- → Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial(2015)301 cited
- → Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies(2022)246 cited
- → Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents(2022)188 cited
- → Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL(2020)140 cited
- → Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion(2019)84 cited